Predictors of attrition with buprenorphine/naloxone treatment in opioid dependent youth

Addictive Behaviors

Volumn 37, Issue 9, 2012, Pages 1046-1053

  Warden, Diane ^a   Subramaniam, Geetha A ^b   Carmody, Thomas ^a   Woody, George E ^c   Minhajuddin, Abu ^a   Poole, Sabrina A ^c   Potter, Jennifer ^d   Fishman, Marc ^e,f   Bogenschutz, Michael ^g   Patkar, Ashwin ^h   Trivedi, Madhukar H ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^c TREATMENT RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e Mountain Manor Treatment Center   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g UNIVERSITY OF NEW MEXICO   (United States)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adherence; Adolescents; Buprenorphine; Opioid dependence; Retention; Youth

Indexed keywords

BUPRENORPHINE PLUS NALOXONE;

ADOLESCENT; ADULT; ARTICLE; DETOXIFICATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; PATIENT COMPLIANCE; PSYCHOSOCIAL CARE; TREATMENT WITHDRAWAL; URINALYSIS;

ADOLESCENT; BUPRENORPHINE; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; NALOXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; RISK FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84862665021     PISSN: 03064603     EISSN: 18736327     Source Type: Journal    
DOI: 10.1016/j.addbeh.2012.04.011     Document Type: Article

References (52)

1. Achenbach T.M. Manual for the youth self report and 1991 profile 1991, Department of Psychiatry, University of Vermont, Burlington, Vermont.
2. Achenbach T. Manual for the young adult self-report and 1997 profiles 1997, Department of Psychiatry, University of Vermont, Burlington, Vermont.
3. Amato L., Davoli M., Ferri M., Gowing L., Perucci C.A. Effectiveness of interventions on opiate withdrawal treatment: An overview of systematic reviews. Drug and Alcohol Dependence 2004, 73:219-226.
4. Amato L., Davoli M., Perucci C.A., Ferri M., Faggiano F., Mattick R.P. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: Available evidence to inform clinical practice and research. Journal of Substance Abuse Treatment 2005, 28:321-329.
5. Armstrong G., Kermode M., Sharma C., Langkham B., Crofts N. Opioid substitution therapy in Manipur and Nagaland, North-East India: Operational research in action. Harm Reduction Journal 2010, 7:29.
6. Bell J., Mutch C. Treatment retention in adolescent patients treated with methadone or buprenorphine for opioid dependence: A file review. Drug and Alcohol Review 2006, 25:167-171.
7. Breen C.L., Harris S.J., Lintzeris N., Mattick R.P., Hawken L., Bell J., et al. Cessation of methadone maintenance treatment using buprenorphine: Transfer from methadone to buprenorphine and subsequent buprenorphine reductions. Drug and Alcohol Dependence 2003, 71:49-55.
8. Burns L., Randall D., Hall W.D., Law M., Butler T., Bell J., et al. Opioid agonist pharmacotherapy in New South Wales from 1985 to 2006: Patient characteristics and patterns and predictors of treatment retention. Addiction 2009, 104:1363-1372.
9. Clemmey P., Payne L., Fishman M. Clinical characteristics and treatment outcomes of adolescent heroin users. Journal of Psychoactive Drugs 2004, 36:85-94.
10. Compton W.M., Volkow N.D. Abuse of prescription drugs and the risk of addiction. Drug and Alcohol Dependence 2006, 83S:S4-S7.
11. Connock M., Juarez-Garcia A., Jowett S., Frew E., Liu Z., Taylor R.J. Methadone and buprenorphine for the management of opioid dependence: A systematic review and economic evaluation. Health Technology Assessment 2007, 11:1-171. iii-iv.
12. Davoli M., Perucci C.A., Forastiere F., Doyle P., Rapiti E., Zaccarelli M., et al. Risk factors for overdose mortality: A case-control study within a cohort of intravenous drug users. International Journal of Epidemiology 1993, 22:273-277.
13. Drug Abuse Warning Network (DAWN) National estimates, drug-related emergency department visits for 2004-2009 Retrieved from. https://dawninfo.samhsa.gov/data/default.asp?met=All.
14. Fischer G., Gombas W., Eder H., Jagsch R., Peternell A., Stuhlinger G., et al. Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction 1999, 94:1337-1347.
15. Garfein R.S., Vlahov D., Galai N., Doherty M.C., Nelson K.E. Viral infections in short-term injection drug users: The prevalence of hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. American Journal of Public Health 1996, 86:655-661.
16. Gerra G., Borella F., Zaimovic A., Moi G., Bussandri M., Bubici C., et al. Buprenorphine versus methadone for opioid dependence: Predictor variables for treatment outcome. Drug and Alcohol Dependence 2004, 75:37-45.
17. Gossop M. The development of a Short Opiate Withdrawal Scale (SOWS). Addictive Behaviors 1990, 15:487-490.
18. Gowing L., Ali R., White J.M. Buprenorphine for the management of opioid withdrawal. Cochrane Database of Systematic Reviews 2009, 3:CD002025.
19. Hopfer C.J., Mikulich S.K., Crowley T.J. Heroin use among adolescents in treatment for substance use disorders. Journal of the American Academy of Child and Adolescent Psychiatry 2000, 39:1316-1323.
20. Hser Y.I., Hoffman V., Grella C.E., Anglin M.D. A 33-year follow-up of narcotics addicts. Archives of General Psychiatry 2001, 58:503-508.
21. Johnson R.E., Chutuape M.A., Strain E.C., Walsh S.L., Stitzer M.L., Bigelow G.E. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. The New England Journal of Medicine 2000, 343:1290-1297.
22. Johnston L.D., O'Malley P.M., Bachman J.G., Schulenberg J.E. Monitoring the future: National results on adolescent drug use: Overview of key findings, 2010 2011, Institute for Social Research, The University of Michigan, Ann Arbor.
23. Kakko J., Svanborg K.D., Kreek M.J., Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: A randomized, placebo-controlled trial. Lancet 2003, 22:662-668.
24. Kampman K.M., Alterman A.I., Volpicelli J.R., Maany I., Muller E.S., Luce D.D., et al. Cocaine withdrawal symptoms and initial urine toxicology results predict treatment attrition in outpatient cocaine dependence treatment. Psychology of Addictive Behaviors 2001, 15:52-59.
25. Katz E.C., Schwartz R.P., King S., Highfield D.A., O'Grady K.E., Billings T., et al. Brief vs. extended buprenorphine detoxification in a community treatment program: Engagement and short-term outcomes. The American Journal of Drug and Alcohol Abuse 2009, 35:63-67.
26. Lee J.D., Grossman E., DiRocco D., Gourevitch M.N. Home buprenorphine/naloxone induction in primary care. Journal of General Internal Medicine 2008, 24:226-232.
27. Leonardi C., Hanna N., Laurenzi P., Fagetti R. Multi-centre observational study of buprenorphine use in 32 Italian drug addiction centres. Drug and Alcohol Dependence 2008, 94:125-132. I.D.A.C. Group.
28. Levy S., Vaughan B.L., Angulo M., Knight J.R. Buprenorphine replacement therapy for adolescents with opioid dependence: Early experience from a children's hospital-based outpatient treatment program. Journal of Adolescent Health 2007, 40:477-482.
29. Marsch L.A., Bickel W.K., Badger G.J., Stothart M.E., Quesnel K.J., Stanger C., et al. Comparison of pharmacological treatments for opioid-dependent adolescents: A randomized controlled trial. Archives of General Psychiatry 2005, 62:1157-1164.
30. Miele G.M., Carpenter K.M., Smith Cockerham M., Dietz Trautman K., Blaine J., Hasin D.S. Concurrent and predictive validity of the Substance Dependence Severity Scale (SDSS). Drug and Alcohol Dependence 2000, 59:77-88.
31. Mintzer I.L., Eisenberg M., Terra M., MacVane C., Himmelstein D.U., Woolhandler S. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings. Annals of Family Medicine 2007, 5:146-150.
32. Motamed M., Marsch L.A., Solhkhah R., Bickel W.K., Badger G.J. Differences in treatment outcomes between prescription opioid-dependent and heroin-dependent adolescents. Journal of Addiction Medicine 2008, 2:158-164.
33. Needle R., Fisher D.G., Weatherby N., Chitwood D., Brown B., Cesari H., et al. Reliability of self-reported HIV risk behaviors of drug users. Psychology of Addictive Behaviors 1995, 9:242-250.
34. NIDA Risk behavior survey 1993, National Institute on Drug Abuse, Community Research Branch, Rockville, MD. 3rd ed.
35. Pani P.P., Maremmani I., Pirastu R., Tagliamonte A., Gessa G.L. Buprenorphine: A controlled clinical trial in the treatment of opioid dependence. Drug and Alcohol Dependence 2000, 60:39-50.
36. Peduzzi P., Concato J., Kemper E., Holford T.R., Feinstein A.R. A simulation study of the number of events per variable in logistic regression analysis. Journal of Clinical Epidemiology 1996, 49:1373-1379.
37. Roux P., Carrieri M.P., Cohen J., Ravaux I., Poizot-Martin I., Dellamonica P., et al. Retention in opioid substitution treatment: A major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment. Clinical Infectious Diseases 2009, 49:1433-1440.
38. Scherbaum N., Heppkausen K., Rist F. Is premature termination of opiate detoxification due to intensive withdrawal or craving?. Fortschritte der Neurologie-Psychiatrie 2004, 72:14-20.
39. Schottenfeld R.S., Pakes J.R., Kosten T.R. Prognostic factors in buprenorphine- versus methadone-maintained patients. The Journal of Nervous and Mental Disease 1998, 186:35-43.
40. Sees K.L., Delucchi K.L., Masson C., Rosen A., Clark H.W., Robillard H., et al. Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: A randomized controlled trial. Journal of the American Medical Association 2000, 8:1303-1310.
41. Soyka M., Zingg C., Koller G., Kuefner H. Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: Results from a randomized study. The International Journal of Neuropsychopharmacology 2008, 11:641-653.
42. Stein M.D., Cioe P., Friedmann P.D. Brief report: Buprenorphine retention in primary care. Journal of General Internal Medicine 2005, 20:1038-1041.
43. Strain E.C., Stitzer M.L., Liebson I.A., Bigelow G.E. Buprenorphine versus methadone in the treatment of opioid-dependent cocaine users. Psychopharmacology 1994, 116:401-406.
44. Strain E.C., Stitzer M.L., Liebson I.A., Bigelow G.E. Comparison of buprenorphine and methadone in the treatment of opioid dependence. The American Journal of Psychiatry 1994, 151:1025-1030.
45. Subramaniam G.A., Ives M.L., Stitzer M.L., Dennis M.L. The added risk of opioid problem use among treatment-seeking youth with marijuana and/or alcohol problem use. Addiction 2010, 105:686-698.
46. Subramaniam G.A., Stitzer M.A. Clinical characteristics of treatment-seeking prescription opioid vs. heroin-using adolescents with opioid use disorder. Drug and Alcohol Dependence 2009, 101:13-19.
47. Subramaniam G.A., Warden D., Minhajuddin A., Fishman M.J., Stitzer M.L., Adinoff B., et al. Predictors of abstinence: NIDA multi-site buprenorphine/naloxone treatment trial in opioid dependent youth. Journal of the American Academy of Child and Adolescent Psychiatry 2011, 50:1120-1128.
48. Substance Abuse and Mental Health Services Administration, Treatment Episode Data Set (TEDS).1999-2009 Rockville, MD: National Admissions to Substance Abuse Treatment Services, DASIS Series: S-56, HHS Publication No. (SMA) 11-4646 2011, Substance Abuse and Mental Health Services Administration.
49. Vigezzi P., Guglielmino L., Marzorati P., Silenzio R., De Chiara M., Corrado F., et al. Multimodal drug addiction treatment: A field comparison of methadone and buprenorphine among heroin- and cocaine-dependent patients. Journal of Substance Abuse Treatment 2006, 31:3-7.
50. Walsh S.L., Preston K.L., Bigelow G.E., Stitzer M.L. Acute administration of buprenorphine in humans-Partial agonist and blockade effects. Journal of Pharmacology and Experimental Therapeutics 1995, 274:361-372.
51. Woody G.E., Poole S.A., Subramaniam G., Dugosh K., Bogenschutz M., Abbott P., et al. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth. Journal of the American Medical Association 2008, 300:2003-2011.
52. Zhang Z., Friedman P.D., Gerstein D.R. Does retention matter? Treatment duration and improvement in drug use. Addiction 2003, 98:673-684.